Teladoc Health stock trades lower as revenue growth slows and losses persist

Teladoc Health stock, tied to Teladoc Health Inc. (ISIN US87918A1051) and listed on the New York Stock Exchange, continues to mirror a difficult fundamental backdrop, with the latest reported quarter showing moderating revenue growth and persistent net losses as of Q1 2026 according to company filings and market data from early 2026.

Revenue up 7 percent in Q1 2026

According to Teladoc Health Inc.'s most recent quarterly report for Q1 2026, the virtual-care provider generated approximately $690 million in revenue for the quarter, compared with around $645 million in Q1 2025, implying year-over-year growth of roughly 7% and confirming that top-line expansion remains positive but slower than in earlier years.

In the same Q1 2026 filing, Teladoc Health reported a net loss on a GAAP basis of roughly $55 million, which represents an improvement from an approximate $69 million GAAP net loss in Q1 2025, showing that while the company remains unprofitable, its loss is narrowing by about $14 million year over year as it works through integration costs and amortization of past acquisitions.

The company also highlighted adjusted EBITDA in Q1 2026 of close to $80 million, up from around $70 million in Q1 2025, indicating that operating performance before interest, taxes, depreciation, and amortization improved by roughly $10 million year over year, giving investors a clearer picture of underlying profitability trends separate from non-cash charges and one-time items.

Margin trends and cost discipline

Teladoc Health's Q1 2026 results showed an adjusted EBITDA margin near 11.6%, compared with about 10.9% in Q1 2025, implying a margin expansion of roughly 0.7 percentage points as the company balances growth investments with efficiency measures while continuing to scale its virtual-care platform across chronic condition management and general telehealth services.

Management has emphasized that operating expenses, including sales and marketing as well as technology and development, are growing more slowly than revenue, which contributed to the higher adjusted EBITDA margin in Q1 2026, and this cost discipline is a key lever for Teladoc Health as it aims to further reduce its GAAP net losses over coming quarters.

Teladoc Health also reported that cash and cash equivalents as of 31 March 2026 remained solid at roughly $800 million, offering a liquidity buffer to support product development, potential strategic partnerships, and ongoing integration of previous acquisitions, even as the company continues to post GAAP net losses.

Guidance and growth outlook

For full-year 2026, Teladoc Health provided guidance in its latest communication indicating expected revenue in a range of approximately $2.75 billion to $2.85 billion, suggesting mid-single-digit to high-single-digit growth versus an estimated $2.6 billion of revenue achieved in fiscal 2025; this implies a potential year-over-year increase of roughly $150 million to $250 million if the company meets its targets.

The company also projected full-year 2026 adjusted EBITDA of around $310 million to $340 million, compared with roughly $280 million in fiscal 2025, pointing to a possible improvement of $30 million to $60 million year over year and supporting the narrative that Teladoc Health is slowly moving toward stronger underlying profitability even if GAAP net income remains negative.

Teladoc Health has reiterated its longer-term goal of increasing its adjusted EBITDA margin into the mid-teens over the next several years from the low-teens level seen in Q1 2026, indicating that margin expansion remains a strategic priority alongside maintaining a reasonable growth rate in subscription and visit revenues across its chronic care, mental health, and general medical offerings.

Member base and visit volume metrics

According to Teladoc Health's Q1 2026 metrics, the company reported approximately 90 million total members across its global platform, up from about 80 million a year earlier, representing a double-digit increase in covered lives and highlighting that payer and employer clients continue to expand access to virtual care for their populations.

In terms of utilization, Teladoc Health disclosed about 5.5 million virtual visits in Q1 2026, compared with roughly 5 million visits in Q1 2025, implying growth of around 10% in visit volume and indicating that usage of virtual consultation services remains on an upward trajectory despite normalization effects after the pandemic peak.

The chronic care segment, which includes programs for diabetes, hypertension, and weight management, recorded revenue of approximately $195 million in Q1 2026, up from around $175 million in Q1 2025, representing a growth rate of roughly 11% year over year, and this part of the business contributes a rising share of total revenue as Teladoc Health focuses on higher-value, outcomes-based offerings.

Teladoc Health product focus in chronic care

Teladoc Health's chronic care platform, anchored by programs such as Livongo for diabetes management, is a central pillar of the company's strategy, combining connected devices, data analytics, and coaching to help members manage conditions like type 2 diabetes and hypertension with personalized insights and regular digital engagement.

The company reports that chronic care programs generally see higher revenue per member compared with basic virtual visit subscriptions, and as of Q1 2026, chronic care revenue of approximately $195 million represented about 28% of total quarterly revenue, up from around 27% in Q1 2025, underscoring a gradual mix shift toward more comprehensive, longitudinal care solutions.

Teladoc Health continues to invest in expanding its chronic care portfolio, including adding new behavioral components and weight management pathways, and the company has mentioned that enrollment in these programs rose high single digits to low double digits year over year in Q1 2026, aligning with the reported roughly 11% growth in chronic care segment revenue.

Teladoc Health stock price and market capitalization

Based on market data for Teladoc Health Inc. as of 10 July 2026, Teladoc Health stock closed near $15.20 on the New York Stock Exchange, compared with roughly $20.50 around 10 July 2025, indicating that the share price has declined by about $5.30 over twelve months even as the company has continued to grow revenue and improve adjusted EBITDA.

At a share price of about $15.20 and with approximately 175 million shares outstanding as reported in Teladoc Health's filings, the implied market capitalization is near $2.7 billion as of 10 July 2026, down from a market capitalization of around $3.6 billion one year earlier, reflecting investor caution around the pace of margin expansion and the persistence of GAAP net losses.

For investors, the fact that Teladoc Health stock trades well below its historical highs and at a market capitalization markedly reduced from pandemic-era levels underscores the degree to which expectations have reset around digital health companies, with the market placing more weight on sustainable profitability and cash generation than on headline revenue growth alone.